Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric aprepitant for prevention of chemotherapy-induced nausea and vomiting
2011-000651-16Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Aprepitant plus ondansetron with Ondansetron alone (2 arms). Primary endpoint: Complete Response in overall phase. Started May 2011; status: completed.
02
Drugs
aprepitantondansetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2011-000651-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000651-16.